PubMed Health⌕ Search

PubMed · 7642068

[Doppler tissue imaging: current status and future prospects].

Abstract

Colour Doppler myocardial imaging is a new technique which allows the visualization in the colour Doppler of myocardial tissues, instead of blood pool imaging. To permit the acquisition of this information some modifications are essential in the machine. The gain has to be reduced so that, firstly, the echoes from ventricular walls were similar to those from the blood pool. Secondly the Doppler velocity range has to be reduced to correspond to the normal velocity of the ventricular wall. These modifications allow the tissue echoes to pass the clutter filter and to be displayed in colour on the video screen. This technique may be able to evaluate the velocity of myocardial tissue, the acceleration and the strength within the myocardial wall with these maps, obtained by modifications in the software, called Velocity Map, Acceleration Map, Energy Map. The clinical applications of this technique are: 1) in the area of myocardial functions e.g.: measurements, volumes, diastolic functions; 2) in the area of myocardial ischemia e.g.: wall motion abnormalities, viability studies, perfusion with contrast agents, stress echo, infarct identification; 3) in the area of myocardial depolarisation e.g.: arrhythmias evaluation, ablation monitoring. Doppler tissue imaging in spite of good results obtained, needs a large clinical studies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Caso, G R Sutherland, A Fleming, W N McDicken. 1995. [Doppler tissue imaging: current status and future prospects].. https://pubmed.ncbi.nlm.nih.gov/7642068/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗